Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2021 | Hepatocellular Carcinoma | Research

Human nuclear receptors (NRs) genes have prognostic significance in hepatocellular carcinoma patients

Authors: Guangtao Sun, Kejian Sun, Chao Shen

Published in: World Journal of Surgical Oncology | Issue 1/2021

Abstract

Background

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality in the world.

Method

We downloaded the mRNA profiles and clinical information of 371 HCC patients from The Cancer Genome Atlas (TCGA) database. The consensus clustering analysis with the mRNA levels of 48 nuclear receptors (NRs) was performed by the “ConsensusClusterPlus.” The univariate Cox regression analysis was performed to predict the prognostic significance of NRs on HCC. The risk score was calculated by the prognostic model constructed based on eight optimal NRs. Then multivariate Cox regression analysis was performed to determine whether the risk score is an independent prognostic signature. Finally, the nomogram based on multiple independent prognostic factors was used to predict the long-term survival of HCC patients.

Results

The prognostic model constructed based on the eight optimal NRs (NR1H3, ESR1, NR1I2, NR2C1, NR6A1, PPARD, PPARG, and VDR) could effectively predict the prognosis of HCC patients as an independent prognostic signature. Moreover, the nomogram was constructed based on multiple independent prognostic factors including risk score and tumor node metastasis (TNM) stage and could better predict the long-term survival for 3- and 5-year of HCC patients.

Conclusion

Our results provided novel evidences that NRs could act as the potential prognostic signatures for HCC patients.

Available only for authorised users

Jiang C, Cheng G, Liao M, Huang J. Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis. World J Surg Oncol. 2021;19(1):81. https://doi.org/10.1186/s12957-021-02188-4.CrossRefPubMedPubMedCentral

Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol. 2016;25(2):74–85. https://doi.org/10.1016/j.suronc.2016.03.002.CrossRefPubMed

Bruix J, Gores GL, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–55. https://doi.org/10.1136/gutjnl-2013-306627.CrossRefPubMedPubMedCentral

Wang EA, Stein JP, Bellavia RJ, Broadwell SR. Treatment options for unresectable HCC with a focus on SIRT with yttrium-90 resin microspheres. Int J Clin Pract. 2017;71(11):e12972.CrossRef

Sala S, Ampe C. An emerging link between LIM domain proteins and nuclear receptors. Cell Mol Life Sci. 2018;75(11):1959–71. https://doi.org/10.1007/s00018-018-2774-3.CrossRefPubMed

Khorasanizadeh S, Rastinejad F. Visualizing the architectures and interactions of nuclear receptors. Endocrinology. 2016;157(11):4212–21. https://doi.org/10.1210/en.2016-1559.CrossRefPubMedPubMedCentral

Romagnolo DF, Zempleni J, Selmin OI. Nuclear receptors and epigenetic regulation: opportunities for nutritional targeting and disease prevention. Adv Nutr. 2014;5(4):373–85. https://doi.org/10.3945/an.114.005868.CrossRefPubMedPubMedCentral

Dasgupta S, Lonard DM, O’Malley BW. Nuclear receptor coactivators: master regulators of human health and disease. Annu Rev Med. 2014;65(1):279–92. https://doi.org/10.1146/annurev-med-051812-145316.CrossRefPubMed

Weikum ER, Liu X, Ortlund EA. The nuclear receptor superfamily: a structural perspective. Protein Sci. 2018;27(11):1876–92. https://doi.org/10.1002/pro.3496.CrossRefPubMedPubMedCentral

10.

Shiota M, Eto M. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. Int J Urol. 2016;23(5):360–9. https://doi.org/10.1111/iju.13091.CrossRefPubMed

11.

Garattini E, Bolis M, Gianni M, Paroni G, Fratelli M, Terao M. Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeutic targets in breast-cancer. Oncotarget. 2016;7(27):42661–82. https://doi.org/10.18632/oncotarget.7410.CrossRefPubMedPubMedCentral

12.

Triki M, Lapierre M, Cavailles V, Mokdad-Gargouri R. Expression and role of nuclear receptor coregulators in colorectal cancer. World J Gastroenterol. 2017;23(25):4480–90. https://doi.org/10.3748/wjg.v23.i25.4480.CrossRefPubMedPubMedCentral

13.

Vacca M, Degirolamo C, Massafra V, Polimeno L, Mariani-Costantini R, Palasciano G, et al. Nuclear receptors in regenerating liver and hepatocellular carcinoma. Mol Cell Endocrinol. 2013;368(1-2):108–19. https://doi.org/10.1016/j.mce.2012.06.025.CrossRefPubMed

14.

Parris TZ. Pan-cancer analyses of human nuclear receptors reveal transcriptome diversity and prognostic value across cancer types. Sci Rep. 2020;10(1):1873. https://doi.org/10.1038/s41598-020-58842-6.CrossRefPubMedPubMedCentral

15.

Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572–3. https://doi.org/10.1093/bioinformatics/btq170.CrossRefPubMedPubMedCentral

16.

Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22.CrossRef

17.

Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):37–44.CrossRef

18.

Newman AM, Liu CL, Green MR, Gentles AJ, Feng WG, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7. https://doi.org/10.1038/nmeth.3337.CrossRefPubMedPubMedCentral

19.

Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–70. https://doi.org/10.1200/JCO.2007.12.9791.CrossRefPubMed

20.

Xu F, Jin TQ, Zhu YW, Dai CL. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37(1):110. https://doi.org/10.1186/s13046-018-0777-4.CrossRefPubMedPubMedCentral

21.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef

22.

Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, et al. Hepatocellular carcinoma: from clinical practice to evidence-based treatment protocols. World J Hepatol. 2015;7(20):2274–91. https://doi.org/10.4254/wjh.v7.i20.2274.CrossRefPubMedPubMedCentral

23.

Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepato. 2006;45(4):529–38. https://doi.org/10.1016/j.jhep.2006.05.013.CrossRef

24.

EASL-EORTC. Easl-eortc clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2011;56(4):908–43.

25.

Wang X, Hassan W, Jabeen Q, Khan GJ, Iqbal F. Interdependent and independent multidimensional role of tumor microenvironment on hepatocellular carcinoma. Cytokine. 2018;103:150–9. https://doi.org/10.1016/j.cyto.2017.09.026.CrossRefPubMed

26.

Shi J, Duncan B, Kuang X. Hydrogen treatment: a novel option in liver diseases. Clin Med (Lond). 2021;21(2):e223–7. https://doi.org/10.7861/clinmed.2020-0370.CrossRef

27.

Khan GJ, Reyaz N, Baloch MB, Cassandra A. Frequency of thalassemia and its association with hepatitis C infection in local population of Pakistan. Biomedica. 2020;36(3):265–71.CrossRef

28.

Lee J, Lee JH, Yoon H, Lee HJ, Jeon H, Nam J. Extraordinary radiation super-sensitivity accompanying with sorafenib combination therapy: what lies beneath? Radiat Oncol J. 2017;35(2):185–8. https://doi.org/10.3857/roj.2017.00262.CrossRefPubMedPubMedCentral

29.

Siao JU, Tsai CC, Liang TJ, Chiang CL, Liang HL, Chen IS, et al. Adjuvant hepatic arterial infusion chemotherapy is beneficial for selective patients with hepatocellular carcinoma undergoing surgical treatment. Int J Surg. 2017;45:35–41.CrossRef

30.

Zheng H, Yang Y, Han J, Jiang WH, Chen C, Wang MC, et al. TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling. Sci Rep. 2016;6(1):37070. https://doi.org/10.1038/srep37070.CrossRefPubMedPubMedCentral

31.

Liu R, Wang G, Zhang C, Bai D. A prognostic model for hepatocellular carcinoma based on apoptosis-related genes. World J Surg Oncol. 2021;19(1):70. https://doi.org/10.1186/s12957-021-02175-9.CrossRefPubMedPubMedCentral

32.

Wu M, Liu Z, Li X, Zhang A, Lin D, Li N. Analysis of potential key genes in very early hepatocellular carcinoma. World J Surg Oncol. 2019;17(1):77. https://doi.org/10.1186/s12957-019-1616-6.CrossRefPubMedPubMedCentral

33.

Sukocheva OA. Estrogen, estrogen receptors, and hepatocellular carcinoma: are we there yet? World J Gastroenterol. 2018;24(1):1–4. https://doi.org/10.3748/wjg.v24.i1.1.CrossRefPubMedPubMedCentral

34.

Syed V. TGF-beta signaling in cancer. J Cell Biochem. 2016;117(6):1279–87. https://doi.org/10.1002/jcb.25496.CrossRefPubMed

35.

Khan GJ, Gao Y, Gu M, Wang L, Khan S, Naeem F, et al. TGF-beta1 causes EMT by regulating N-acetyl glucosaminyl transferases via downregulation of non muscle myosin II-A through JNK/P38/PI3K pathway in lung cancer. Curr Cancer Drug Targets. 2018;18(2):209–19. https://doi.org/10.2174/1568009617666170807120304.CrossRefPubMed

36.

Bhagyaraj E, Ahuja N, Kumar S, Tiwari D, Gupta S, Nanduri R, et al. TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR. Cell Cycle. 2019;18(24):3589–602. https://doi.org/10.1080/15384101.2019.1693120.CrossRefPubMedPubMedCentral

37.

Hoan NX, Khuyen N, Giang DP, Binh TM, Toan NL, Anh DT, et al. Vitamin D receptor ApaI polymorphism associated with progression of liver disease in Vietnamese patients chronically infected with hepatitis B virus. BMC Med Genet. 2019;20(1):201. https://doi.org/10.1186/s12881-019-0903-y.CrossRefPubMedPubMedCentral

38.

Khan S, Zaki H. Crosstalk between NLRP12 and JNK during hepatocellular carcinoma. Int J Mol Sci. 2020;21(2):496. https://doi.org/10.3390/ijms21020496.CrossRefPubMedCentral

Title: Human nuclear receptors (NRs) genes have prognostic significance in hepatocellular carcinoma patients
Authors: Guangtao Sun
Kejian Sun
Chao Shen
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: World Journal of Surgical Oncology / Issue 1/2021
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-021-02246-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Human nuclear receptors (NRs) genes have prognostic significance in hepatocellular carcinoma patients

Abstract

Background

Method

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Low urinary iodine is a protective factor of central lymph node metastasis in papillary thyroid cancer: a cross-sectional study

Unresected small lymph node assessment predicts prognosis for patients with pT3N0M0 thoracic esophageal squamous cell carcinoma

A novel prognostic model based on epithelial-mesenchymal transition-related genes predicts patient survival in gastric cancer

New classifications of axillary lymph nodes and their anatomical-clinical correlations in breast surgery

Application of ultrasound-guided intranodal lymphangiography and embolisation in cancer patients with postoperative lymphatic leakage

Identification of a prognostic gene signature of colon cancer using integrated bioinformatics analysis